These particles are similar to the virus from which they were derived from; however they lack viral nucleic acid, which results in the best compromise between safety (not infectious) and efficacy (highly immunogenic).

"Our transient expression system which produces recombinant vaccine antigens in the cells of non-transgenic plants has demonstrated its efficiency and medical potential by successfully producing the H5N1 Avian Influenza vaccine candidate in VLPs," said Dr. Louis Vezina, Chief Scientific Officer of Medicago.

"This is an excellent result and a major milestone for Medicago," said Andy Sheldon, President and Chief Executive Officer of Medicago. "VLPs offer a promising avenue for the development of effective vaccines for diseases such as the constantly evolving H5N1 Avian Influenza. Our unique ability to rapidly deliver vaccines that can protect against the multiple variations of viruses will, in our opinion, give our technology a critical advantage over traditional egg-based and cell culture technologies. Using our proprietary plant-based technology, we believe we now have the ability to deliver a VLP vaccine for testing a month after the identification and reception of genetic sequences from the pandemic strain."

Medicago has initiated preclinical studies with its proprietary VLP against H5N1 Avian Influenza virus and is now accumulating data. It is expected results from this first study will be published in the coming weeks. About Medicago

Medicago is a biotechnology company focused on the development, production and commercialization of vaccines and therapeutic protein-based biopharmaceuticals using a proprietary manufacturing system developed from its expertise in the genetic engineering of plants. Medicago's Proficia technology offers speed, flexibility and cost advantages that can greatly improve the accessibility of today's emerging vaccines and biopharmaceuticals for both partners and patients. The Company is developing its own proprietary pipeline of vaccines and also has established collaboration agreements notably with Acambis PLC (LSE: ACM, www.acambis.com) for the development of several products.